Notification

Divine Hira Jewellers IPO is Open!

Apply for the Divine Hira Jewellers IPO through UPI in just minutes.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Alivus Life Sciences Ltd Share Price

₹ 1040.00 16.00 (1.56%)

Mar 17 2025 01:15 PM Pharmaceuticals NSE: ALIVUS

Alivus Life Sciences Ltd Share Price Update

As of the latest trading session, Alivus Life Sciences Ltd share price is currently at 1040, which is up by 16.00 from its previous closing. Today, the stock has fluctuated between 1006.00 and 1050.00. Over the past year, Alivus Life Sciences Ltd has achieved a return of 48.77 %. In the last month alone, the return has been -0.19 %. Read More...

Alivus Life Sciences Ltd Performance

Day Range

Low1006.00 High1050.00

1040.00

52 Week Range

Low 676.50 High 1335.10

1040.00

Alivus Life Sciences Ltd Share Price

5265

543322

ALIVUS

Compare to down-arrow

View

Display

Studies

Open Price

1006.00

Prev. Close

1024.00

Volume (Shares)

10,884

Total traded value

111.56 (₹ Lakhs)

Upper Circuit

1228.80

Lower Circuit

819.20

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Alivus Life Sciences Ltd Fundamentals

(Standalone)

Market Cap (Cr)	12545.50
PE Ratio (TTM)	28.40
Book Value / Share	207.16
Beta	0.43

ROE	21.07%
EPS (TTM)	36.05
Dividend Yield	2.20%
Net Profit Qtr (Cr)	136.96

Alivus Life Sciences Ltd Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023

Particulars	Dec 2024 (Values in Cr)
Revenue	641.84
Operating Expense	467.15
Net Profit	136.96
Net Profit Margin (%)	21.33
Earnings Per Share (EPS)	11.18
EBITDA	200.77
Effective Tax Rate (%)	26.02

Particulars	Dec 2024 (Values in Cr)
Revenue	506.88
Operating Expense	387.95
Net Profit	95.32
Net Profit Margin (%)	18.80
Earnings Per Share (EPS)	7.78
EBITDA	142.89
Effective Tax Rate (%)	25.21

Particulars	Dec 2024 (Values in Cr)
Revenue	588.62
Operating Expense	443.87
Net Profit	111.48
Net Profit Margin (%)	18.93
Earnings Per Share (EPS)	9.10
EBITDA	164.98
Effective Tax Rate (%)	25.79

Particulars	Dec 2024 (Values in Cr)
Revenue	536.60
Operating Expense	410.05
Net Profit	97.94
Net Profit Margin (%)	18.25
Earnings Per Share (EPS)	7.99
EBITDA	144.57
Effective Tax Rate (%)	24.47

Particulars	Dec 2024 (Values in Cr)
Revenue	572.80
Operating Expense	413.82
Net Profit	118.77
Net Profit Margin (%)	20.73
Earnings Per Share (EPS)	9.69
EBITDA	174.25
Effective Tax Rate (%)	26.08

Particulars	Dec 2024 (Values in Cr)
Revenue	2283.21
Operating Expense	1663.97
Net Profit	470.89
Net Profit Margin (%)	20.62
Earnings Per Share (EPS)	38.43
EBITDA	686.29
Effective Tax Rate (%)	25.40

Particulars	Dec 2024 (Values in Cr)
Revenue	2161.22
Operating Expense	1561.57
Net Profit	466.96
Net Profit Margin (%)	21.60
Earnings Per Share (EPS)	38.11
EBITDA	671.25
Effective Tax Rate (%)	25.71

Particulars	Dec 2024 (Values in Cr)
Revenue	2123.21
Operating Expense	1572.99
Net Profit	418.72
Net Profit Margin (%)	19.72
Earnings Per Share (EPS)	35.63
EBITDA	630.77
Effective Tax Rate (%)	25.87

Particulars	Dec 2024 (Values in Cr)
Revenue	1885.17
Operating Expense	1415.04
Net Profit	351.58
Net Profit Margin (%)	18.64
Earnings Per Share (EPS)	32.61
EBITDA	591.88
Effective Tax Rate (%)	25.34

Particulars	Dec 2024 (Values in Cr)
Revenue	1537.31
Operating Expense	1128.24
Net Profit	313.10
Net Profit Margin (%)	20.36
Earnings Per Share (EPS)	29.04
EBITDA	483.96
Effective Tax Rate (%)	25.64

Particulars	Dec 2024 (Values in Cr)
Book Value / Share	190.35
ROE %	21.07
ROCE %	27.94
Total Debt to Total Equity	0.01
EBITDA Margin	30.06

Particulars	Dec 2024 (Values in Cr)
Book Value / Share	174.51
ROE %	22.28
ROCE %	29.80
Total Debt to Total Equity	0.01
EBITDA Margin	31.06

Particulars	Dec 2024 (Values in Cr)
Book Value / Share	167.66
ROE %	29.83
ROCE %	42.20
Total Debt to Total Equity	0.00
EBITDA Margin	29.71

Particulars	Dec 2024 (Values in Cr)
Book Value / Share	768.11
ROE %	60.91
ROCE %	96.75
Total Debt to Total Equity	0.00
EBITDA Margin	31.40

Particulars	Dec 2024 (Values in Cr)
Book Value / Share	2049.45
ROE %	127.84
ROCE %	185.60
Total Debt to Total Equity	0.00
EBITDA Margin	31.48

Particulars	Dec 2024 (Values in Cr)
Cash & Short Term Investments	301.59
Total Assets	2850.41
Total Liabilities	2850.41
Total Equity	2332.32
Share Outstanding	122527172
Price to Book Ratio	4.07
Return on Assets (%)	16.51
Return on Capital (%)	20.19

Particulars	Dec 2024 (Values in Cr)
Cash & Short Term Investments	309.39
Total Assets	2702.14
Total Liabilities	2702.14
Total Equity	2138.20
Share Outstanding	122527172
Price to Book Ratio	2.24
Return on Assets (%)	17.28
Return on Capital (%)	21.84

Particulars	Dec 2024 (Values in Cr)
Cash & Short Term Investments	512.16
Total Assets	2471.00
Total Liabilities	2471.00
Total Equity	2054.31
Share Outstanding	122527172
Price to Book Ratio	2.74
Return on Assets (%)	16.94
Return on Capital (%)	20.38

Particulars	Dec 2024 (Values in Cr)
Cash & Short Term Investments	115.59
Total Assets	1997.07
Total Liabilities	1997.07
Total Equity	752.74
Share Outstanding	9800450
Price to Book Ratio	0.00
Return on Assets (%)	17.60
Return on Capital (%)	46.71

Particulars	Dec 2024 (Values in Cr)
Cash & Short Term Investments	9.99
Total Assets	1725.60
Total Liabilities	1725.60
Total Equity	401.69
Share Outstanding	1960090
Price to Book Ratio	0.00
Return on Assets (%)	18.14
Return on Capital (%)	77.94

Particulars	Dec 2024 (Values in Cr)
Net Income	631.29
Cash from Operations	576.47
Cash from Investing	-116.48
Cash from Financing	-279.44
Net change in Cash	17.59
Free Cash Flow	705.44

Particulars	Dec 2024 (Values in Cr)
Net Income	628.60
Cash from Operations	459.57
Cash from Investing	-146.74
Cash from Financing	-387.59
Net change in Cash	-228.33
Free Cash Flow	622.36

Particulars	Dec 2024 (Values in Cr)
Net Income	564.92
Cash from Operations	735.75
Cash from Investing	-122.22
Cash from Financing	-78.79
Net change in Cash	396.56
Free Cash Flow	867.92

Particulars	Dec 2024 (Values in Cr)
Net Income	470.94
Cash from Operations	496.67
Cash from Investing	-68.73
Cash from Financing	-213.78
Net change in Cash	105.59
Free Cash Flow	564.67

Particulars	Dec 2024 (Values in Cr)
Net Income	421.06
Cash from Operations	287.54
Cash from Investing	-50.51
Cash from Financing	-136.55
Net change in Cash	7.93
Free Cash Flow	338.70

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	36.74	19.75	2.00	281.55	35.10 / 77.70
BLISS GVS PHARMA LTD	114.55	15.01	1.19	1207.02	92.25 / 184.95
CIPLA LTD	1461.60	23.66	4.16	118041.00	1317.60 / 1702.00
FERMENTA BIOTECH LIMITED	243.95	20.21	2.47	717.97	145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT	2657.45	52.71	26.91	45018.81	1825.05 / 3087.95

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	36.74	22.13	6.24	281.55	35.10 / 77.70
AMRUTAJAN HEALTH LTD	588.35	34.49	5.71	1700.96	548.05 / 861.40
ASTRAZENECA PHARMA IND LT	7660.30	114.25	28.18	19150.75	4050.15 / 8139.85
BLISS GVS PHARMA LTD	114.55	14.88	1.17	1207.02	92.25 / 184.95

Alivus Life Sciences Ltd Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

1023.85

-0.01

Bullish Moving Averages 7

Bearish Moving Averages 9

5 Days 1020.00
26 Days 1035.20
10 Days 1017.00
50 Days 1052.00
12 Days 1017.80
100 Days 1053.40
20 Days 1027.60
200 Days 1006.40

1013.77
PIVOT

First Resistance	1047.48
Second Resistance	1077.52
Third Resistance	1111.23

First Support	983.73
Second Support	950.02
Third Support	919.98

RSI	48.54
MACD	-17.38
Commodity Channel Index (CCI)	19.17

ADX	25.57
Williams % R	-32.42

Alivus Life Sciences Ltd Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

13.4 Promoter Holdings

74.99 FII

6.74 DII

4.85 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Nirma Limited	Shareholding of Promoter and Promoter Group	9.1896285E7	75.0
Polar Capital Funds Plc - Healthcare Opportunities	Public Shareholding	3423757.0	2.79
Quant Mutual Fund - Quant Flexi Cap Fund	Public Shareholding	1832022.0	1.5
Massachusetts Institute Of Technology	Public Shareholding	1570000.0	1.28

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2023-10-17	22.5	Interim	2023-10-17	Equity shares	2023-03-24	21.0	Interim	2023-03-24	Equity shares	2022-09-15	10.5	Final	2022-09-17	Equity shares	2021-11-22	10.5	Interim	2021-11-23	Equity shares

Learn More About Stocks

Zydus Life Gets Final USFDA Approval for Eluxadoline Tablets

Zydus Lifesciences Ltd. receives final USFDA approval for Eluxadoline Tablets, 75 mg and 100 mg, securing 180-day shared exclusivity in the US market.

17 Mar, 2025 | 2 Min. read

Galaxy Surfactants Declares ₹18 Per Share Interim Dividend for FY25

Galaxy Surfactants announces an interim dividend of ₹18 per equity share for FY25. The record date is March 20, 2025, with payment to be made within 30 days.

17 Mar, 2025 | 2 Min. read

Dalmia Bharat Begins Production at 2.4 MTPA Cement Unit in Assam

Dalmia Bharat starts commercial production at its expanded 2.4 MTPA cement grinding unit in Assam, increasing its total manufacturing capacity to 49 MTPA.

17 Mar, 2025 | 2 Min. read

KEC International Secures Orders Worth Rs 1,267 Crores Across Sectors

KEC International secures new orders worth Rs 1,267 crores in T&D and cables. The company’s YTD order intake surpasses Rs 23,300 crores, reflecting 35% growth.

17 Mar, 2025 | 2 Min. read

Coromandel International Acquires 53% Stake in NACL Industries for ₹820 Crore

Coromandel International Ltd acquires a 53.13% stake in NACL Industries for ₹820 crore, expanding its presence in the crop protection market. Learn more about the deal.

13 Mar, 2025 | 3 Min. read

BEML Signs MoUs with Siemens India and Dragflow Italy for Rail, Dredging

BEML partners with Siemens India for rail solutions and Dragflow Italy for dredging. The collaboration expands BEML’s presence in key infrastructure sectors.

13 Mar, 2025 | 3 Min. read

Jio and Airtel team up with Starlink to revolutionise Indian internet

Jio and Airtel’s partnership with Starlink accelerates satellite broadband in India, improving connectivity in rural areas. Learn how this deal impacts consumers and the market.

13 Mar, 2025 | 4 Min. read

Ola Electric Announces Holi Flash Sale on S1 Range e-Scooters

Ola Electric offers discounts up to Rs 26,750 on S1 e-scooters in Holi flash sale. Check prices, offers, and benefits before the sale ends.

13 Mar, 2025 | 4 Min. read

Bharti Airtel Partners with SpaceX to Launch Starlink Internet in India

Bharti Airtel collaborates with Elon Musk’s SpaceX to bring Starlink satellite internet to India, expanding broadband access in rural and underserved areas.

12 Mar, 2025 | 3 Min. read

Adani Green Commissions 250 MW Solar Project in Kadapa, Andhra Pradesh

Adani Green Energy commissions a 250 MW solar project in Kadapa, Andhra Pradesh, raising its total renewable energy capacity to 12,591.1 MW.

12 Mar, 2025 | 3 Min. read

About Alivus Life Sciences Ltd

Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018. A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs).

Indian Private

Headquarters

Solapur

Founded

2011

NSE Symbol

ALIVUS

Exchange

NSE,BSE

Yasir Yusufali Rawjee

Managing Director & CEO

Vinod Naik

Executive Director

Manju Agarwal

Independent Non Exe. Director

Taruvai Laxminarayanan Easwar

Independent Non Exe. Director

HIREN KARSANBHAI PATEL

Chairman (Non-Executive)

KAUSHIKBHAI NANDUBHAI PATEL

Independent Director

We have something for everyone

Explore More Investment Options

Start Investing

Stocks

Secure and enhance your financial future today

Invest

IPOs

Your gateway to future financial opportunities

Invest

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x

Invest

US Stocks

Discover opportunities to invest in elite FAANG stocks

Invest

Frequently Asked Questions

What is the Share Price of Alivus Life Sciences Ltd?

Answer Field: The share price of Alivus Life Sciences Ltd for NSE is ₹ 1040 and for BSE is ₹ 1038.35.

What is the Market Cap of Alivus Life Sciences Ltd?

Answer Field: The market cap of Alivus Life Sciences Ltd for NSE is ₹ 1,25,45.50 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Alivus Life Sciences Ltd?

Answer Field: The 52 Week High and Low of Alivus Life Sciences Ltd for NSE is ₹ 1335.10 and ₹ 676.50 and for BSE is ₹ 1335.00 and ₹ 666.05.

How to Buy Alivus Life Sciences Ltd share?

Answer Field: You can trade in Alivus Life Sciences Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Alivus Life Sciences Ltd?

Answer Field: The 1 year returns on the stock has been 48.77%.

What is the Current Share Price of Alivus Life Sciences Ltd?

Answer Field: Alivus Life Sciences Ltd share price is for NSE ₹ 1040 & for BSE ₹ 1038.35 as on Mar 17 2025 01:15 PM.

What is the Market Cap of Alivus Life Sciences Ltd Share?

Answer Field: The market cap of Alivus Life Sciences Ltd for NSE ₹ 1,25,45.50 & for BSE ₹ 0.0 as on Mar 17 2025 01:15 PM.

What is the P/E Ratio of Alivus Life Sciences Ltd Share?

Answer Field: As on Mar 17 2025 01:15 PM the price-to-earnings (PE) ratio for Alivus Life Sciences Ltd share is 28.40.

What is the PB ratio of Alivus Life Sciences Ltd Share?

Answer Field: As on Mar 17 2025 01:15 PM, the price-to-book (PB) ratio for Alivus Life Sciences Ltd share is 207.16.

How to Buy Alivus Life Sciences Ltd Share?

Answer Field: You can trade in Alivus Life Sciences Ltd shares with Bajaj Broking by opening a demat accountopens in a new tab.

How to Buy Alivus Life Sciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Alivus Life Sciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Alivus Life Sciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Scan to download

Download from App Store

Download from Play Store

9 lakh+ Users

4.3+ App Rating

4 Languages

₹4300+ Cr MTF Book

Open Demat Account

Divine Hira Jewellers IPO is Open!

Open a Free Demat Account

Trade Now, Pay Later with up to 4x

Track Market Movers Instantly

Alivus Life Sciences Ltd Share Price

Alivus Life Sciences Ltd Share Price Update

Alivus Life Sciences Ltd Performance

Day Range

52 Week Range

Alivus Life Sciences Ltd Share Price

Open Price

1006.00

Prev. Close

1024.00

Volume (Shares)

10,884

Total traded value

111.56 (₹ Lakhs)

Upper Circuit

1228.80

Lower Circuit

819.20

Alivus Life Sciences Ltd Fundamentals

Alivus Life Sciences Ltd Financials

Revenue

Net income

Alivus Life Sciences Ltd Technicals

Over 1 Month

-0.19 %

Over 3 Months

0.57 %

Over 6 Months

-20.79 %

Over 1 Year

48.77 %

Over 3 Years

29.03 %

Over 5 Years

0.00 %

Alivus Life Sciences Ltd Future

Future: Price

Discount/Premium

Active Calls

Active Puts

Alivus Life Sciences Ltd Shareholding Pattern

Stock Holding

View Live Stock Screeners

Holding

Public

13.4

Promoter Holdings

74.99

FII

6.74

DII

4.85

Promoter Shares(Pledge Percentage)

0.0

Holding %

Pledges % of promoter shares %

MF Holding %

FII Holding %

Alivus Life Sciences Ltd

Learn More About Stocks

Zydus Life Gets Final USFDA Approval for Eluxadoline Tablets

Galaxy Surfactants Declares ₹18 Per Share Interim Dividend for FY25

Dalmia Bharat Begins Production at 2.4 MTPA Cement Unit in Assam

KEC International Secures Orders Worth Rs 1,267 Crores Across Sectors

About Alivus Life Sciences Ltd

Parent Organisation

Indian Private

Headquarters

Solapur

Founded

2011

NSE Symbol

ALIVUS

Exchange

NSE,BSE

Yasir Yusufali Rawjee